Top 3 new drug approvalsHere are 3 of the top new drug approvals in late December and early January.
Serious risks associated with SGLT2 inhibitorsFDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.
FDA warns of joint pain for DPP-4 diabetes drugs
FDA warns of joint pain for DPP-4 diabetes drugsFDA warned this week that several leading drugs for type 2 diabetes may cause severe and disabling joint pain. FDA said that sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain, and added a new Warning and Precaution about this risk to the labels of all dipeptidyl peptidase-4 (DPP-4) inhibitors.
ADA: Canagliflozin may be cost-effective treatment option for type 2 diabetes with diet, exercise: StudiesIn adult patients with type 2 diabetes inadequately controlled on metformin monotherapy—the current standard of treatment— canagliflozin (Invokana) 100 mg and 300 mg reduced relative risk for myocardial infarction (1.6% and 3.0%) and congestive heart failure (2.7% and 4.0%), as compared to sitagliptin 100 mg, according to findings of the health economic simulation analysis presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
GLP-1 targeted therapy may help diabetes patientsThe role of ophthalmologists will become increasingly more vital in the management of type 2 diabetes as the numbers of patients with the disease is projected to double by 2030. Exenatide may prove to be an important adjunct to current oral anti-diabetes drugs.
FDA evaluates diabetes drugs for possible increased risk of pancreatitis, precancerous cellular changes of pancreas